Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD
Articles > Article ยท 2016
Authors: Abdullah SAYINER, Jadwiga A. Wedzicha, Donald Banerji, Kenneth R. Chapman, Jorgen Vestbo, Nicolas Roche, Timothy Ayers, Chau Thach, Robert Fogel, Francesco Patalano, Claus F. Vogelmeier
NEW ENGLAND JOURNAL OF MEDICINE, Journal Indexed in SCI Expanded, International, 2016, vol 374, pp 2222-2234
Summary
BACKGROUND Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic obstructive pulmonary disease (COPD) who have a high risk of exacerbations. The role of treatment with a LABA-LAMA regimen in these patients is unclear.